Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinogen replacement to prevent intracranial haemorrhage after thrombolysis in ischemic stroke: pilot randomized trial
2020-005242-41Phase 3Active
- Sponsor
- Azienda USL di Bologna
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Fibrinogen human in ischemic stroke and acute intracranial hemorrhage (ICH) (2 arms), sponsored by Azienda USL di Bologna. Primary endpoint: Intracranial haemorrhage rate. Started May 2021; status: active.
02
Drugs
Fibrinogen human
03
Conditions
ischemic strokeacute intracranial hemorrhage (ICH)
Beyond the preview
Go deeper on 2020-005242-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005242-41.